Icure Pharmaceutical Incorporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 163.59 million compared to KRW 504.86 million a year ago. Net loss was KRW 9,609.08 million compared to KRW 439.67 million a year ago. Basic loss per share from continuing operations was KRW 530 compared to KRW 27 a year ago. Basic loss per share was KRW 530 compared to KRW 27 a year ago.
For the nine months, sales was KRW 733.02 million compared to KRW 789.92 million a year ago. Net loss was KRW 22,129.03 million compared to KRW 4,936.08 million a year ago. Basic loss per share from continuing operations was KRW 1,220 compared to KRW 303 a year ago. Basic loss per share was KRW 1,220 compared to KRW 303 a year ago.